Optima Health PLC First Day of Dealings on AIM

RNS Number : 7106F

Optima Health PLC

26 September 2024

 

 

 

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY IN OR INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION.

 

This announcement does not constitute or form part of an offer to sell or issue or a solicitation of an offer to subscribe for or buy any securities nor should it be relied upon in connection with any contract or commitment whatsoever in any jurisdiction. Investors should not subscribe for or purchase any securities referred to in this announcement except solely on the basis of the information contained in the admission document, including the risk factors set out therein, published by Optima Health plc (the "Company" or "Optima") on 23 September 2024 in connection with the admission of the ordinary shares in the capital of the Company to trading on AIM, a market operated by London Stock Exchange plc (the "Admission Document").

 

 

Optima Health plc

("Optima", the "Company", and, together with its subsidiaries, the "Group")

 

First Day of Dealings on AIM

 

-      UK's largest provider of corporate health and wellbeing solutions

-      Cash generative and profitable (on adjusted basis)

-     FY2024 revenues of 110.9 million and adjusted EBITDA of £18.0 million

 

LONDON, UK., 26 September 2024, Optima Health, the UK's leading provider of technology enabled corporate health and wellbeing solutions, is pleased to announce the admission of its Ordinary Shares to trading on AIM, a market operated by London Stock Exchange plc ("Admission").  

 

Dealings in the Company's ordinary shares of £0.01 each in the capital of the Company ("Ordinary Shares") will commence at 8.00 a.m. today under the ticker "OPT" (ISIN:  GB00BRSCY602). On Admission, the Company will have 88,776,226 Ordinary Shares in issue and no Ordinary Shares held in treasury.

 

Jonathan Thomas, Chief Executive Officer of Optima Health, commented: "We are delighted to begin Optima Health's journey as an AIM-listed company. As an independent business, we are well positioned to continue our successful track record of growth, both organic and through successful acquisition and integration, within the strong and growing occupational health market in the UK. Being a publicly listed company will provide us with an opportunity to build and deliver significant value for our shareholders and employees and we look forward to beginning this exciting new chapter in our story."

 

Admission

The Directors believe that Admission will be an important step in the Group's development and will assist the Group in its development by raising its public profile, widening its shareholder base, providing potential future access to development capital to progress its current and future pipeline of proprietary products and enabling it to expand within its core areas and expand its commercial partnerships. It will also provide the Group with the ability to incentivise its employees through share incentive plans, which should assist it in continuing to attract, retain and motivate high calibre employees.

 

No new capital was raised through an offer or sale of Ordinary Shares to institutional investors or the public in connection with Admission. Prior to Admission, the Optima Health executive management team subscribed for new Ordinary Shares in the Company, in connection with the settlement of the Company's legacy senior management share incentive plan, as further described in the Admission Document.

 

Unless otherwise indicated, capitalised terms in this Announcement have the meaning given to them in the Admission Document.

 

 

Enquiries

 

Optima Health Jonathan Thomas, CEO Heidi Giles, CFO   [phone] [e-mail] Nominated Adviser and Corporate Broker Panmure Liberum Limited Emma Earl / Will Goode/ Mark Rogers Rupert Dearden     [phone] UK Financial PR Adviser ICR Consilium Mary-Jane Elliott / Angela Gray / Chris Welsh [e-mail]

 

 

About Optima Health

Optima Health is the UK's leading provider of occupational health and wellbeing services, directly influencing and improving people's lives for 25 years. Optima Health's incredible team of professionals quickly and effectively encapsulate client's needs, supporting organisations of all shapes and sizes. Through tailored solutions and innovative systems, Optima Health offers unparalleled clinical expertise to its clients. These solutions ensure that processes are simple and allow its clients to spend more time focusing on their employees driving a healthy, high-performing workplace. For more information visit www.optimahealth.co.uk.

 

 

 

IMPORTANT NOTICES

 

This announcement does not constitute, or form part of, any offer or invitation to sell, allot or issue, or any solicitation of any offer to purchase or subscribe for, any securities in the Company in any jurisdiction nor shall it, or any part of it, or the fact of its distribution, form the basis of, or be relied on in connection with or act as an inducement to enter into, any contract or commitment therefor.

 

No reliance may be placed, for any purpose whatsoever, on the information or opinions contained in this announcement or on its accuracy, fairness or completeness. To the fullest extent permitted by applicable law or regulation, no undertaking, representation or warranty, express or implied, is given by or on behalf of the Company, Panmure Liberum Limited ("Panmure Liberum"), or their respective parent or subsidiary undertakings or the subsidiary undertakings of any such parent undertakings or any of their respective directors, officers, partners, employees, agents, affiliates, representatives or advisers or any other person as to the accuracy, sufficiency, completeness or fairness of the information, opinions or beliefs contained in this announcement and no responsibility or liability is accepted by any of them for any errors, omissions or inaccuracies in such information, opinions or beliefs or for any loss, cost or damage suffered or incurred, howsoever arising, from any use, as a result of the reliance on, or otherwise in connection with, this announcement.

 

Panmure Liberum, which is authorised and regulated by the Financial Conduct Authority is acting only for the Company in connection with Admission and is not acting for or advising any other person, or treating any other person as its client, in relation thereto, or giving advice to any other person in relation to the matters contained herein. Such persons should seek their own independent legal, investment and tax advice as they see fit. Panmure Liberum's responsibilities, as the Company's nominated adviser under the AIM Rules for Nominated Advisers and AIM Rules for Companies will be owed solely to the London Stock Exchange and not to the Company, to any of its directors or to any other person in respect of a decision to subscribe for or otherwise acquire Shares in reliance on the Admission Document. No representation or warranty, express or implied, is made by Panmure Liberum or the Company or their respective affiliates, directors, officers, employees or advisers as to any of its contents.

 

This announcement does not form the basis of or constitute any offer or invitation to sell or issue, or any solicitation of any offer to purchase or subscribe for any Shares or any other securities nor shall it (or any part of it) or the fact of its distribution, form the basis of, or be relied on in connection with, any contract or commitment therefor. No offer or sale of the Shares has been and will not be registered under the applicable securities laws of the United States, Australia, Canada, Japan or South Africa. Subject to certain exceptions, the Shares may not be offered or sold in the United States, Australia, Canada, Japan or South Africa or to, or for the account or benefit of, any national, resident or citizen of the United States, Australia, Canada, Japan or South Africa. There will be no public offer of the Shares in the United States, Australia, Canada, Japan or South Africa.

 

This announcement may include statements that are, or may be deemed to be, "forward-looking statements". These forward-looking statements may be identified by the use of forward-looking terminology, including the terms "believes", "estimates", "plans", "projects", "anticipates", "expects", "intends", "may", "will" or "should" or, in each case, their negative or other variations or comparable terminology, or by discussions of strategy, plans, objectives, goals, future events or intentions. These statements reflect beliefs of the Directors (including based on their expectations arising from pursuit of the Company's strategy) as well as assumptions made by the Directors and information currently available to the Company. Although the Directors consider that these beliefs and assumptions are reasonable, by their nature, forward-looking statements involve known and unknown risks, uncertainties, assumptions and other factors that may cause the Company's actual financial condition, results of operations, cash flows, liquidity or prospects to be materially different from any future such metric expressed or implied by such statements. Past performance cannot be relied upon as a guide to future performance and should not be taken as a representation that trends or activities underlying past performance will continue in the future. Forward-looking statements speak only as of the date they are made. No representation is made or will be made that any forward-looking statements will come to pass or prove to be correct.

 

Whilst the contents of this announcement are believed to be true and accurate as at the date of its publication, no representation or warranty is made as to such contents continuing to be true and accurate at any point in the future.

 

For the avoidance of doubt, the contents of the Company's websites and social media accounts are not incorporated by reference into, and do not form part of, this announcement.

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

 

END

 

 

MSCFELLLZKLBBBQ